MX347829B - Molécula fv de unión a antígeno multivalente. - Google Patents

Molécula fv de unión a antígeno multivalente.

Info

Publication number
MX347829B
MX347829B MX2014000816A MX2014000816A MX347829B MX 347829 B MX347829 B MX 347829B MX 2014000816 A MX2014000816 A MX 2014000816A MX 2014000816 A MX2014000816 A MX 2014000816A MX 347829 B MX347829 B MX 347829B
Authority
MX
Mexico
Prior art keywords
antigen
binding molecule
binding
polypeptide
molecule
Prior art date
Application number
MX2014000816A
Other languages
English (en)
Other versions
MX2014000816A (es
Inventor
Little Melvyn
Le Gall Fabrice
Original Assignee
Affimed Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Therapeutics Ag filed Critical Affimed Therapeutics Ag
Publication of MX2014000816A publication Critical patent/MX2014000816A/es
Publication of MX347829B publication Critical patent/MX347829B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un aspecto, la presente invención se relaciona con una molécula de unión de antígeno específica para albúmina y CD3 que comprende dos cadenas polipeptidicas, teniendo cada cadena polipeptídica al menos cuatro dominios variables en una orientación que evita la formación de Fv y las dos cadenas polipeptídicas se dimerizan con otra formando por lo tanto una molécula de unión de antígeno multivalente. Sobre cada una de las dos cadenas polipeptídicas los cuatro dominios variables están arreglados en el orden VLA-VHB-VLB-VHA del N-terminal al C-terminal del polipéptido. Las composiciones de la molécula de unión de antígeno y los métodos de uso de la molécula de unión de antígeno o las composiciones de la misma para el tratamiento de varias enfermedades también son proporcionadas aquí.
MX2014000816A 2011-07-22 2011-07-22 Molécula fv de unión a antígeno multivalente. MX347829B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2011/062673 WO2013013700A1 (en) 2011-07-22 2011-07-22 Multivalent antigen-binding fv molecule

Publications (2)

Publication Number Publication Date
MX2014000816A MX2014000816A (es) 2014-07-09
MX347829B true MX347829B (es) 2017-05-15

Family

ID=44719851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000816A MX347829B (es) 2011-07-22 2011-07-22 Molécula fv de unión a antígeno multivalente.

Country Status (8)

Country Link
JP (1) JP5938473B2 (es)
CN (1) CN103687879B (es)
AU (1) AU2011373925B2 (es)
BR (1) BR112014001573B8 (es)
CA (1) CA2842649C (es)
MX (1) MX347829B (es)
RU (1) RU2613368C2 (es)
WO (1) WO2013013700A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3148580B1 (en) 2014-05-29 2021-01-20 MacroGenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
CN106661119A (zh) 2014-07-01 2017-05-10 辉瑞公司 双特异性异二聚化双抗体及其用途
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EP3250601A4 (en) 2015-01-26 2018-07-11 MacroGenics, Inc. Multivalent molecules comprising dr5-binding domains
KR102537102B1 (ko) 2015-05-29 2023-05-25 엠피베나 테라퓨틱스, 인크. 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
SI3456346T1 (sl) 2015-07-30 2021-11-30 Macrogenics, Inc. Molekule za vezavo PD-1 in LAG-3 in postopki za uporabo le-teh
GEP20217328B (en) 2015-12-14 2021-12-10 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
US20170233472A1 (en) 2016-02-17 2017-08-17 Macrogenics, Inc. ROR1-Binding Molecules, and Methods of Use Thereof
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE
AR110424A1 (es) 2016-12-23 2019-03-27 Macrogenics Inc Moléculas de unión a adam9 y métodos de uso de las mismas
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
AU2018228719B2 (en) * 2017-02-28 2023-03-30 Affimed Gmbh Tandem diabody for CD16A-directed NK-cell engagement
KR20200013230A (ko) * 2017-06-05 2020-02-06 누맙 세러퓨틱스 아게 적어도 cd3 및 hsa를 표적화하는 헤테로-이량체 다중 특이적 항체 포맷
CA3080248A1 (en) 2017-10-26 2019-05-02 Saint-Gobain Glass France Add-on part having an integrated camera module
KR20200098590A (ko) 2017-12-12 2020-08-20 마크로제닉스, 인크. 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
US11685781B2 (en) 2018-02-15 2023-06-27 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
US20210238286A1 (en) * 2018-06-07 2021-08-05 Cullinan Management, Inc. Multi-specific binding proteins and methods of use thereof
RU2738802C1 (ru) * 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
EP1500665B1 (en) * 2002-04-15 2011-06-15 Chugai Seiyaku Kabushiki Kaisha METHODS FOR CONSTRUCTING scDb LIBRARIES
EP1400534B1 (en) 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
JPWO2005056605A1 (ja) * 2003-12-12 2007-12-06 中外製薬株式会社 ３量体以上の受容体を認識する改変抗体
EP1870458B1 (en) * 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US9315584B2 (en) * 2009-03-25 2016-04-19 Tohoku University LH-type bispecific antibody
ES2582001T3 (es) * 2010-02-25 2016-09-08 Affimed Gmbh Molécula que se une a antígeno y usos de la misma

Also Published As

Publication number Publication date
RU2013157040A (ru) 2015-08-27
BR112014001573B1 (pt) 2022-08-30
WO2013013700A1 (en) 2013-01-31
BR112014001573A2 (pt) 2017-02-21
RU2613368C2 (ru) 2017-03-16
JP2014527515A (ja) 2014-10-16
AU2011373925A1 (en) 2014-01-16
CA2842649A1 (en) 2013-01-31
CA2842649C (en) 2020-01-21
JP5938473B2 (ja) 2016-06-22
AU2011373925B2 (en) 2016-04-28
BR112014001573B8 (pt) 2022-11-08
MX2014000816A (es) 2014-07-09
CN103687879A (zh) 2014-03-26
CN103687879B (zh) 2016-05-04

Similar Documents

Publication Publication Date Title
MX347829B (es) Molécula fv de unión a antígeno multivalente.
EP2371866A3 (en) Multivalent antigen-binding Fv molecule
HRP20211343T1 (hr) Protutijela protiv dkk-1
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ761188A (en) Antibody molecules to tim-3 and uses thereof
MX2021007006A (es) Anticuerpo anti-calicreina-2 humanizado.
MY191428A (en) Antigen binding molecules comprising a tnf family ligand trimer
MX353931B (es) Anticuerpos que se unen a ox40 y sus usos.
WO2015173756A3 (en) Bispecific antibodies with engineered ch1-cl interfaces
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ626269A (en) Anti-phf-tau antibodies and their uses
WO2015138600A3 (en) Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
TN2014000134A1 (en) Therapeutic peptides
MX366223B (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
MX2022013667A (es) Construcciones polipeptidicas de union al antigeno que comprenden cadenas ligeras kappa y lambda y usos de estas.
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
MX2018009498A (es) Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1.
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
NZ616761A (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
TN2014000120A1 (en) Cd27l antigen binding proteins
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2014015043A (es) Anticuerpos anti-trka humanizados con sustituciones de aminoacidos.
GB201005064D0 (en) Biological products

Legal Events

Date Code Title Description
FG Grant or registration